Celldex Therapeutics Inc
Statements
Cash Flow
Celldex Therapeutics Inc (CLDX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -57 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24 | -20 | -35 | -21 | -24 | -20 | -28 | -17 | -14 | -15 | -13 | -11 | -11 | -11 | -12 | -11 | -12 | -5.2 | -18 | -12 | -16 | -15 | -25 | -22 | -35 | -22 | -29 | -27 | -19 | -33 | -41 | -29 | -55 | -32 | -54 | -44 | -49 | -64 | -66 | -57 | -236 | |
| 1.0 | 1.2 | 1.6 | 1.2 | 1.2 | 1.2 | 1.3 | 1.0 | 0.8 | 0.7 | 1.4 | 1.2 | 1.2 | 1.1 | 1.2 | 1.1 | 0.9 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | -12 | 0.8 | 0.9 | 0.9 | 0.8 | 3.9 | 0.2 | 1.5 | 6.5 | |
| 3.8 | 3.6 | 3.5 | 3.5 | 2.7 | 2.6 | 2.5 | 2.0 | 1.8 | 1.8 | 1.7 | 1.5 | 0.7 | 0.7 | 0.7 | 0.7 | 1.3 | 1.3 | 1.3 | 1.5 | 3.0 | 3.1 | 3.2 | 3.5 | 4.5 | 4.5 | 4.3 | 5.2 | 7.1 | 7.2 | 7.2 | 7.6 | 9.6 | 9.8 | 9.3 | 9.2 | 8.8 | 8.9 | 8.5 | 8.4 | 35 | |
| 3.8 | 3.6 | 6.9 | 4.5 | 5.9 | -17 | 98 | -4.3 | -5.0 | 0.1 | 5.0 | 0.4 | -1.4 | 1.0 | 0.9 | -1.2 | 1.9 | 15 | 1.7 | 1.6 | 4.4 | 3.1 | 2.6 | -2.3 | 4.4 | 4.0 | 4.3 | 5.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.7 | 7.0 | -9.5 | 2.2 | -5.2 | 0.2 | -8.8 | 2.6 | -2.7 | -6.5 | -2.0 | -0.5 | 0.8 | -2.5 | -1.5 | 0.1 | -0.3 | 1.4 | -4.0 | -1.0 | 2.2 | 1.8 | -5.7 | 15 | -14 | 0.1 | -3.0 | -1.5 | 13 | 5.0 | -13 | 2.8 | -19 | 7.4 | -8.5 | 4.2 | 9.8 | 8.5 | 4.3 | 8.5 | 31 | |
| 0.8 | 0.6 | 0.4 | 0.9 | 0.3 | 0.2 | 0.3 | 0.3 | 0.1 | 0.2 | 0.2 | 0.3 | 0.1 | 0.1 | 0.2 | 0.9 | 0.2 | 0.2 | 0.6 | 0.1 | 0.2 | 0.4 | 0.6 | 0.7 | 0.3 | 0.2 | 0.6 | 0.4 | 0.2 | 0.7 | 0.3 | 0.3 | 0.6 | 0.8 | 0.3 | 0.7 | 0.4 | 1.0 | 1.6 | 3.2 | 6.3 | |
| 15 | 28 | 22 | 36 | 1.7 | -13 | 15 | 13 | -2.2 | 3.3 | 16 | -8.0 | 5.5 | 3.2 | 22 | -109 | -43 | 31 | 43 | -14 | -227 | -19 | 10 | 25 | 23 | 31 | 53 | 1.2 | 12 | -171 | -315 | -47 | 48 | 24 | 43 | 50 | 61 | 55 | 72 | -256 | -67 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 8.3 | 3.3 | 13 | 8.7 | 11 | 18 | 12 | 8.3 | 5.5 | 3.6 | 4.2 | 7.2 | 2.5 | 2.4 | 1.6 | 165 | 4.5 | 0.0 | 0.1 | 0.0 | 272 | 0.4 | 0.3 | 0.1 | 2.3 | – | 0.7 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 8.3 | 3.3 | 13 | 8.7 | 11 | 18 | 12 | 8.3 | 5.5 | 3.6 | 4.2 | 7.2 | 2.5 | 2.4 | 1.6 | 165 | 4.5 | 0.0 | 0.1 | 0.0 | 272 | 0.4 | 0.3 | 0.1 | 2.3 | 1.4 | 0.7 | 0.1 | 0.3 | 217 | 436 | 3.7 | 1.2 | 0.4 | 0.2 | 0.1 | 0.8 | 1.3 | 0.3 | 325 | 327 | |
| -0.7 | 11 | 0.0 | 24 | -11 | -14 | -0.5 | 4.1 | -11 | -8.5 | 7.2 | -12 | -3.2 | -5.4 | 11 | 45 | -50 | 26 | 25 | -26 | 29 | -33 | -14 | 3.1 | -9.8 | 11 | 25 | -26 | -7.1 | 14 | 80 | -72 | -6.3 | -8.0 | -11 | 5.9 | 13 | -7.2 | 6.9 | 12 | 24 | |
| -25 | -21 | -36 | -22 | -25 | -20 | -28 | -18 | -14 | -16 | -13 | -11 | -11 | -11 | -12 | -12 | -12 | -5.5 | -19 | -12 | -17 | -15 | -25 | -23 | -36 | -22 | -29 | -28 | -19 | -33 | -41 | -30 | -55 | -33 | -55 | -45 | -49 | -65 | -67 | -61 | -242 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.